pepcid complete tablet (chewable)
mcneil consumer healthcare division of johnson & johnson inc - famotidine; calcium carbonate; magnesium hydroxide - tablet (chewable) - 10mg; 800mg; 165mg - famotidine 10mg; calcium carbonate 800mg; magnesium hydroxide 165mg - antacids and adsorbents
pepcid duo milligram tablets chewable
mcneil healthcare (ireland) ltd - famotidine, magnesium hydroxide, calcium carbonate - tablets chewable - milligram - h2-receptor antagonists
eviplera tenofovir disoproxil fumarate 300 mg /emtricitabine 200 mg /rilpivirine (as hcl) 25 mg tablet bottle
gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil fumarate, quantity: 300 mg; rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; polysorbate 20; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; iron oxide red; macrogol 3350; indigo carmine aluminium lake - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna =< 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).
pepcid ac film-coated 10 milligram film coated tablet
mcneil healthcare (ireland) ltd - famotidine - film coated tablet - 10 milligram - h2-receptor antagonists
pepcid 20 milligram film coated tablet
merck sharp and dohme limited - famotidine - film coated tablet - 20 milligram
pepcid 40 milligram film coated tablet
merck sharp and dohme limited - famotidine - film coated tablet - 40 milligram
pepcid ac tablet
mcneil consumer healthcare division of johnson & johnson inc - famotidine - tablet - 10mg - famotidine 10mg - histamine h2-antagonists
pepcid- famotidine tablet, film coated
bausch health us llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - pepcid tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: pepcid tablets are indicated in adults for the: reduction of the risk of duodenal ulcer recurrence. pepcid is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2) receptor antagonists. risk summary available data with h2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background ris
dasatinib sun dasatinib 100 mg tablet bottle pack
sun pharma anz pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; lactose monohydrate; hyprolose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.
dasatinib sun dasatinib 100 mg tablet blister pack
sun pharma anz pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose monohydrate; croscarmellose sodium; calcium hydrogen phosphate; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.